HUP0103199A2 - Glükózfelvétel-fokozó alkalmazása az apoptosis csökkentésére - Google Patents

Glükózfelvétel-fokozó alkalmazása az apoptosis csökkentésére

Info

Publication number
HUP0103199A2
HUP0103199A2 HU0103199A HUP0103199A HUP0103199A2 HU P0103199 A2 HUP0103199 A2 HU P0103199A2 HU 0103199 A HU0103199 A HU 0103199A HU P0103199 A HUP0103199 A HU P0103199A HU P0103199 A2 HUP0103199 A2 HU P0103199A2
Authority
HU
Hungary
Prior art keywords
prevention
reduction
glucose uptake
cells
uptake enhancer
Prior art date
Application number
HU0103199A
Other languages
English (en)
Inventor
Antoine Michel Alain Bril
Robin Edwin Buckingham
Nassirah Khandoudi
Original Assignee
Smithkline Beecham Laboratoires Pharmaceutique
Smithkline Beecham Plc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Smithkline Beecham Laboratoires Pharmaceutique, Smithkline Beecham Plc. filed Critical Smithkline Beecham Laboratoires Pharmaceutique
Publication of HUP0103199A2 publication Critical patent/HUP0103199A2/hu
Publication of HUP0103199A3 publication Critical patent/HUP0103199A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány a szívizomsejtek, hasnyálmirigy béta-sejtek, endothelialissejtek és idegsejtek közül kiválasztott differenciált sejtekapoptosisának a csökkentésére vagy megelőzésére, valamint sejtekischaemiás insultus, szérum deprováció vagy citokin aktiváció általindukált apoptosisának a csökkentésére vagy megelőzésére, továbbá aszív post-ischaemiás károsodásának, különösen a szívizominfarktusmegelőzésére vagy csökkentésére és/vagy a szív myocardialis ischaemiautáni funkcionális gyógyulásának a javítására szolgáló új eljárásokravonatkozik, amelyek során egy ilyen kezelést igénylő humán vagynemhumán emlősnek egy glükózfelvétel-fokozó, így egy dioxo-tiazolidin,például 5-[4-(2-[N-metil-N-(2-piridil)-amino]-etoxi}benzil]- 2,4-dioxo-tiazolidin hatásos, nemtoxikus mennyiségét adják be. Ó
HU0103199A 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis HUP0103199A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method

Publications (2)

Publication Number Publication Date
HUP0103199A2 true HUP0103199A2 (hu) 2002-05-29
HUP0103199A3 HUP0103199A3 (en) 2002-08-28

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103199A HUP0103199A3 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Country Status (26)

Country Link
EP (2) EP1098639B1 (hu)
JP (1) JP2002521326A (hu)
KR (1) KR20010079551A (hu)
CN (1) CN1310620A (hu)
AP (1) AP2001002036A0 (hu)
AT (1) ATE288746T1 (hu)
AU (1) AU5053799A (hu)
BG (1) BG105250A (hu)
BR (1) BR9912117A (hu)
CA (1) CA2338211A1 (hu)
DE (1) DE69923687T2 (hu)
DK (1) DK1098639T3 (hu)
EA (1) EA200100165A1 (hu)
ES (1) ES2237929T3 (hu)
HK (1) HK1037865A1 (hu)
HU (1) HUP0103199A3 (hu)
ID (1) ID26986A (hu)
IL (1) IL140664A0 (hu)
NO (1) NO20010292L (hu)
OA (1) OA11579A (hu)
PL (1) PL345627A1 (hu)
PT (1) PT1098639E (hu)
SI (1) SI1098639T1 (hu)
SK (1) SK1012001A3 (hu)
TR (1) TR200100207T2 (hu)
WO (1) WO2000004890A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3073700A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Troglitazone-containing medicinal compositions for inhibiting apoptosis
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
HUP0002941A3 (en) * 1996-09-12 2001-11-28 Sankyo Company Ltd Chuo Ku Glutathione reductase activity potentiator containing troglitazone
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
CA2311125C (en) * 1997-11-19 2011-01-18 Takeda Chemical Industries, Ltd. Apoptosis inhibitor
AU2781899A (en) * 1998-02-24 1999-09-15 Trustees Of The University Of Pennsylvania, The Use of a cardiac purinoceptor to effect cellular glucose uptake
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
BR9912117A (pt) 2001-04-10
NO20010292D0 (no) 2001-01-18
EP1516617A2 (en) 2005-03-23
OA11579A (en) 2004-06-01
EP1098639B1 (en) 2005-02-09
ES2237929T3 (es) 2005-08-01
AU5053799A (en) 2000-02-14
NO20010292L (no) 2001-03-08
ATE288746T1 (de) 2005-02-15
CN1310620A (zh) 2001-08-29
ID26986A (id) 2001-02-22
WO2000004890A1 (en) 2000-02-03
HK1037865A1 (en) 2002-02-22
PT1098639E (pt) 2005-06-30
BG105250A (en) 2001-11-30
SI1098639T1 (hu) 2005-08-31
HUP0103199A3 (en) 2002-08-28
SK1012001A3 (en) 2001-08-06
DE69923687D1 (de) 2005-03-17
TR200100207T2 (tr) 2001-05-21
PL345627A1 (en) 2002-01-02
KR20010079551A (ko) 2001-08-22
EA200100165A1 (ru) 2001-08-27
CA2338211A1 (en) 2000-02-03
DK1098639T3 (da) 2005-06-13
EP1098639A1 (en) 2001-05-16
IL140664A0 (en) 2002-02-10
JP2002521326A (ja) 2002-07-16
AP2001002036A0 (en) 2001-03-31
DE69923687T2 (de) 2006-04-06

Similar Documents

Publication Publication Date Title
RS51343B (sr) Nova kompozicija i njena upotreba
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
ATE257703T1 (de) 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
NO20021281L (no) Vaskul¶r beleggingssammensetning
ATE481093T1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
RU94017851A (ru) Ингибиторы протеолитических ферментов на основе производных сахарина, фармацевтическая композиция для лечения дегеративных заболеваний
HUP0302845A2 (hu) 4-Fluor-N-indán-2-il-benzamid és gyógyszerként történő felhasználása
EA200401522A1 (ru) Противотуберкулёзный препарат: композиции и способы
MY121136A (en) Novel heterocyclic sulfonamides.
MY137777A (en) Inhibitors of aspartyl protease
EP1078923A3 (en) Process for the preparation of benzothiophene derivatives
HUP0301161A2 (hu) Az 5-[4-[2-[N-metil-N-(2-piridil)-amino]-etoxi]-benzil]-tiazolidin-2,4-dion-maleát új polimorf formái és eljárás azok előállítására
HUP0102146A2 (hu) Heterociklussal szubsztituált új amidok, előállításuk és alkalmazásuk
MA25356A1 (fr) Polymorphe du sel de l'acide maleique 5-(4-(2-n-methyl-n(2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2,4-dione.
HUP0103199A2 (hu) Glükózfelvétel-fokozó alkalmazása az apoptosis csökkentésére
EA200601144A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину
RS49793B (sr) Postupak za dobijanje derivata tiazolidindiona
CA2473202A1 (en) Pharmaceutical composition for regeneration of cirrhotic liver
MA27077A1 (fr) Derives de 2-amino-4-heteroarylethyl thiazoline et leur utilisation comme inhibiteurs de no-synthase inductible
TR200002790T2 (tr) 5-(4-(2-(N-metil-N-2-piridil) amino)etoksi) benzil)tiazolidin-2,4-dion içeren terkip
MY129475A (en) Process for the preparation of substituted thiazolidinedione
ATE549404T1 (de) Verfahren zum screening eines transmembranenzymhemmstoffs
PE99499A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
UY25051A1 (es) Composiciones para el tratamiento de diabetes mellitus
HUP0103870A2 (hu) Glükózfelvétel-fokozó alkalmazása a szív post-ischaemiás károsodásának a csökkentésére

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees